The FY2025 (Dec) proxy of Regeneron Pharmaceuticals names 11 peer companies for pay. Among Regeneron Pharmaceuticals and these peers, CEO pay was the lowest of 8 and total shareholder return was 5th highest of 8.
8th highest of 8in Regeneron Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
$7.3M$36.7M
5th highest of 8in Regeneron Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
$105$671
Pay peer group, FY2025 (Dec) proxy
| Eli Lilly & Co | ||
| AbbVie | ||
| Incyte | ||
| Gilead Sciences | ||
| Amgen | ||
| Bristol Myers Squibb | ||
| Merck & Co. | ||
| Alnylam Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| BioMarin Pharmaceutical Inc. | Not disclosed | Not disclosed |
| Biogen | Not disclosed | Not disclosed |
| Vertex Pharmaceuticals Incorporated | Not disclosed | Not disclosed |
11 companies
Changes by year
FY2024 (Dec) proxy
- RemovedSeagen Inc.pay peer groupBased on the recommendation of Pay Governance LLC, the Committee removed Seagen Inc. (whose acquisition by Pfizer Inc. was completed in late 2023) from the Peer Group but otherwise did not make any changes in 2024
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.